Office of the Commissioner of Lobbying of Canada Office of the Commissioner of Lobbying of Canada

Language selection

Registry of Lobbyists

Registration - Consultant

Sunovion Pharmaceuticals Canada Inc. / Kate Dalgleish, Consultant

Registration Information

Client name: Sunovion Pharmaceuticals Canada Inc.
Lobbyist name: Kate Dalgleish, Consultant
Initial registration start date: 2020-10-20
Registration status: Inactive
Registration Number: 926625-367714

Associated Communications

Total Number of Communication Reports: 6

Monthly communication reports in the last 6 months: 0

Version 1 of 2 (2020-10-20 to 2020-11-16)

Version 1 of 2 (2020-10-20 to 2020-11-16)



Responsible Officer Name

This is the responsible officer name as provided in the most recent registration for the corporation or organization.

Name Change History:

Sunovion Pharmaceuticals Canada Inc./

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name From To
Sunovion Pharmaceuticals Canada Inc./ 2020-10-20 2021-02-16

Responsible Officer Change History

Sunovion Pharmaceuticals Canada Inc.

Responsible Officer History
Responsible Officer Name From (YYYY-MM-DD) To (YYYY-MM-DD)

All Monthly Communication Reports for Sunovion Pharmaceuticals Canada Inc.

Kate Dalgleish, Compass Rose Group (Consultant)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-6 of 6

  • Sunovion Pharmaceuticals Canada Inc.
    Consultant: Kate Dalgleish
    Designated Public Office Holders who participated in the communication:
    • Helen Gao, Policy Advisor | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2020-12-17
    Posted date: 2021-01-15
    Communication number: 367714-492034 View associated registration
  • Sunovion Pharmaceuticals Canada Inc.
    Consultant: Kate Dalgleish
    Designated Public Office Holders who participated in the communication:
    • Lawrence Cheung, Associate Executive Director | Office of Pharmaceuticals Management | Public Health Agency of Canada (PHAC)
    • Nelson Millar, Senior Policy Analyst | Public Health Agency of Canada (PHAC)
    • N'kem Odita, Policy Analyst | Public Health Agency of Canada (PHAC)

    Subject Matter of the communication: Government Procurement, Health, Research and Development
    Communication date: 2020-12-17
    Posted date: 2021-01-15
    Communication number: 367714-492033 View associated registration
  • Sunovion Pharmaceuticals Canada Inc.
    Consultant: Kate Dalgleish
    Designated Public Office Holders who participated in the communication:
    • Stevie O'Brien, Chief of Staff | Minister's Office | Public Services and Procurement Canada (PSPC)

    Subject Matter of the communication: Government Procurement, Health
    Communication date: 2020-12-17
    Posted date: 2021-01-15
    Communication number: 367714-492032 View associated registration
  • Sunovion Pharmaceuticals Canada Inc.
    Consultant: Kate Dalgleish
    Designated Public Office Holders who participated in the communication:
    • Rodrigo Arancibia, Director | Life Sciences Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    • Benoit Leduc, Senior Project Leader | Life Sciences Industries Directorate | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Government Procurement, Health, Industry
    Communication date: 2020-12-16
    Posted date: 2021-01-15
    Communication number: 367714-491924 View associated registration
  • Sunovion Pharmaceuticals Canada Inc.
    Consultant: Kate Dalgleish
    Designated Public Office Holders who participated in the communication:
    • Fritz-Lionel Adimi, Senior Policy Advisor | Treasury Board Of Canada Secretariat (TBS)

    Subject Matter of the communication: Health
    Communication date: 2020-12-16
    Posted date: 2021-01-15
    Communication number: 367714-491922 View associated registration
  • Sunovion Pharmaceuticals Canada Inc.
    Consultant: Kate Dalgleish
    Designated Public Office Holders who participated in the communication:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    • Tanya Potashnik, Director | Policy & Economic Analysis Branch | Patented Medicine Prices Review Board (PMPRB)
    • Elena Lungu, Manager | Policy Development | Patented Medicine Prices Review Board (PMPRB)
    • Isabel Jaen Raasch, General Counsel | Patented Medicine Prices Review Board (PMPRB)

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2020-12-09
    Posted date: 2021-01-15
    Communication number: 367714-489631 View associated registration

Public offices held: Kate Dalgleish


Date Modified: